Christian Regenbrecht's guest appearances

Christian Regenbrecht

Finding Genius Podcast

FutureTech Podcast

Mary Jo Rapini

Cassie Bjork

Paul Moayyedi

Laura Jana

Gus van der Feltz

Samantha Gladish

Christoph Guger

Andrew Walker

David Heath

David Benrimoh

Cali Estes

Harold Garner

Alyssa Crittenden

David Ewing

Katie Hasson

OwlTail

In this podcast, Dr. Christian Regenbrecht, the CEO of CELLphenomics, talks about 3D cell culture technologies, preclinical efficacy studies, and the changing healthcare landscape. Regenbrecht was a student of biology and philosophy at the University of Bonn, pushed forward toward his postdoc with noted scientist, Hans Lehrach, at the Max Planck Institute for Molecular Genomics in Berlin, and by a young age was already fully immersed in the biotechnology field. From working on improved patient-derived in vitro models to 3D cell culture technologies, preclinical efficacy studies, and more, Regenbrecht was stimulated by the challenges within the scientific arena. Regenbrecht provides an overview of the many innovations that are currently taking place at CELLphenomics. CELLphenomics offers researchers the ability to test compounds with a comprehensive screening approach. Regenbrecht explains the intricacies of cell culture. Patient-derived cell cultures, specifically, are novel multicellular systems freshly isolated from primary organs via mechanical as well as enzymatic dissociation. Within this system, cells grown on a proprietary matrix can grow as 3D organoids—composed of cell clusters preserving the composition of the original tissue. Regenbrecht talks in detail about cell types in tumors, with information on colon tumors. Continuing, he explains the process by which some tumors could metastasize. Regenbrecht discusses the processes to isolate exosomes that are secreted into the cell culture. And as Regenbrecht explains, studying this information, researchers might be able to predict where the next site of metastasization could occur. The mission at CELLphenomics, as an in vitro service provider is to offer quality cell culture models at a fair price, and assist the biotech and pharma industries in the creation of innovative testings for new anti-cancer drugs. In this podcast: How some tumors metastasize What are exosomes? How the biotech industry is changing modern medicine

In this podcast, Dr. Christian Regenbrecht, the CEO of <a href="https://www.cellphenomics.com" rel="nofollow" target="_blank">CELLphenomics</a>, talks about 3D cell culture technologies, preclinical efficacy studies, and the changing healthcare landscape. Regenbrecht was a student of biology and philosophy at the University of Bonn, pushed forward toward his postdoc with noted scientist, Hans Lehrach, at the Max Planck Institute for Molecular Genomics in Berlin, and by a young age was already fully immersed in the biotechnology field. From working on improved patient-derived in vitro models to 3D cell culture technologies, preclinical efficacy studies, and more, Regenbrecht was stimulated by the challenges within the scientific arena. Regenbrecht provides an overview of the many innovations that are currently taking place at CELLphenomics. CELLphenomics offers researchers the ability to test compounds with a comprehensive screening approach. Regenbrecht explains the intricacies of cell culture. Patient-derived cell cultures, specifically, are novel multicellular systems freshly isolated from primary organs via mechanical as well as enzymatic dissociation. Within this system, cells grown on a proprietary matrix can grow as 3D organoids—composed of cell clusters preserving the composition of the original tissue. Regenbrecht talks in detail about cell types in tumors, with information on colon tumors. Continuing, he explains the process by which some tumors could metastasize. Regenbrecht discusses the processes to isolate exosomes that are secreted into the cell culture. And as Regenbrecht explains, studying this information, researchers might be able to predict where the next site of metastasization could occur. The mission at CELLphenomics, as an in vitro service provider is to offer quality cell culture models at a fair price, and assist the biotech and pharma industries in the creation of innovative testings for new anti-cancer drugs. In this podcast: How some tumors metastasize What are exosomes? How the biotech industry is changing modern medicine

The Culture Club – Dr. Christian Regenbrecht, CEO, CELLphenomics

Dr. Christian Regenbrecht, shareholder, CEO, of CELLphenomics, provides an overview of his company’s important work that could assist researchers as they strive to develop new drugs to treat disease. Regenbrecht studied biology and philosophy at the University of Bonn, and continued his postdoc with noted scientist, Hans Lehrach, at the Max Planck Institute for Molecular Genomics in Berlin. Regenbrecht has focused some of his time on improved patient-derived in vitro models, culture technologies, and preclinical efficacy studies. Regenbrecht discusses his extensive work and the innovations that are happening at CELLphenomics. With greater than 400 proprietary patient-derived 3D (PD3D®) cell cultures, CELLphenomics can offer researchers an opportunity to test compounds with a comprehensive screening approach in an, up to, 384 well format. In simplest terms, patient-derived cell cultures are essentially novel multicellular systems newly isolated from primary organs through mechanical and enzymatic dissociation. Within a system such as this, cells that are grown on a proprietary matrix can develop as 3D organoids which are composed of cell clusters preserving the uniquely complex composition of the tissue of origin. Regenbrecht discusses cell types in tumors, specifically focusing on colon tumors. Continuing, he discusses the ways that tumors can metastasize. Regenbrecht explains how they are able to use their processes to isolate exosomes that are secreted into the cell culture. By studying this information, researchers may be able to predict where the next site of metastasization could occur. Regenbrecht explains their mission at CELLphenomics, as a state-of-the-art in vitro service provider positioned to offer high-quality, sensibly priced cell culture models and ultimately assist the biotech and pharma industries to create innovative testings of new anti-cancer drugs. In this podcast: What makes some tumors metastasize? A detailed explanation of exosomes Innovative practices in the biotech industry

Dr. Christian Regenbrecht, shareholder, CEO, of <a href="https://www.cellphenomics.com" rel="nofollow" target="_blank">CELLphenomics</a>, provides an overview of his company’s important work that could assist researchers as they strive to develop new drugs to treat disease. Regenbrecht studied biology and philosophy at the University of Bonn, and continued his postdoc with noted scientist, Hans Lehrach, at the Max Planck Institute for Molecular Genomics in Berlin. Regenbrecht has focused some of his time on improved patient-derived in vitro models, culture technologies, and preclinical efficacy studies. Regenbrecht discusses his extensive work and the innovations that are happening at CELLphenomics. With greater than 400 proprietary patient-derived 3D (PD3D®) cell cultures, CELLphenomics can offer researchers an opportunity to test compounds with a comprehensive screening approach in an, up to, 384 well format. In simplest terms, patient-derived cell cultures are essentially novel multicellular systems newly isolated from primary organs through mechanical and enzymatic dissociation. Within a system such as this, cells that are grown on a proprietary matrix can develop as 3D organoids which are composed of cell clusters preserving the uniquely complex composition of the tissue of origin. Regenbrecht discusses cell types in tumors, specifically focusing on colon tumors. Continuing, he discusses the ways that tumors can metastasize. Regenbrecht explains how they are able to use their processes to isolate exosomes that are secreted into the cell culture. By studying this information, researchers may be able to predict where the next site of metastasization could occur. Regenbrecht explains their mission at CELLphenomics, as a state-of-the-art in vitro service provider positioned to offer high-quality, sensibly priced cell culture models and ultimately assist the biotech and pharma industries to create innovative testings of new anti-cancer drugs. In this podcast: What makes some tumors metastasize? A detailed explanation of exosomes Innovative practices in the biotech industry

Cell Culture – Dr. Christian Regenbrecht, Shareholder, CEO, CELLphenomics – Assisting the Researchers, New Drugs for Disease Treatment